

外資系企業における製造販売後調査(PMS)の傾向

~PhRMA/EFPIA合同調査結果より~



○穂積香織(アッヴィ)²、今井景子(ヤンセンファーマ)¹、小川嘉正(フェリングファーマ)¹、佐藤夫美(ファイザー)²、仙田雅之(サノフィ)¹、塚本はるな(日本イーライリリー)²

欧州製薬団体連合会 $(EFPIA)^2$ 米国研究製薬工業協会(PhRMA)

・2021年度にはPMSは承認品目66品目中48品目(73%)で実施され、昨年に比べ実施品目の割合は少し増えているが、大きな傾向の違いはなかった。うち一般使用成績調査は35%、特定使用成績調査は48%、使用成績 比較調査は2%、データベース調査は15%であり、この割合も2020年度と同様の傾向であった。

・PMSの実施計画書については、初回面談時までに40%の製品で実施計画書を提出しており、PMSに関連する初回問合せも70%が初回面談後の問合せ時までに来ており、PMSの検討が早くから始まっていることが認めら れる。一方でPMDAとの実施計画書等の合意は74%の調査で専門協議後に至っている。

・PMSの実施体制は、8割強の会社で実施計画書の内容についてグローバルの承認が必要であった。また照会事項の回答も、全ての事項ではないが9割近くの会社でグローバルの確認を必要としており、PMSは日本独自 の制度に従って実施するが、グローバルが一定の関与をしていることがわかる。

・また、同意取得の状況は、89%の会社でなんらかの同意取得を行っており、そのうち64%の会社では、全例調査においても同意取得を行っていた。

・PMSの結果公表に関し、94%の会社で実施計画書又は実施要綱に調査結果の公表について記載されていた。再審査を目的としての実施が中心であったが、適正使用情報を早期に提供することやデータジェネレーション といった点から中間や最終報告を含め、積極的にPMSのデータが公表されていた。グローバルの関与や、同意の取得が進んでいる点からも今後もPMSのデータ活用の傾向は強くなっていくと考えられた。 →なお、2020年、2021年はコロナ禍での調査実施であったことも踏まえ、PMDAへの対応についても報告する。


PhRMA-EFPIA Joint Survey 2021

- Review Period
- Review time for new drug approvals in FY2021
- PMS
 - PMS in approved new drugs in FY2021
 - PMS plan PMDA interaction/agreement timing
 - PMS organization and global interaction
 - PMS trend informed consent and disclosure
 - PMS under Covid-19


This results of analysis is based on the following companies, and the result of three overlapping companies are counted as one time


Participating companies:

 PhRMA (11 companies) Abbvie, Amgen, Biogen Japan, Bristol-Myers Squibb, CSL Behring*, Eli Lilly, GlaxoSmithKline*,



PMS Planning/All case survey trend Protocol was planned based on **Protocol was agreed with PMDA** "Procedures for Developing Postbased on "Procedures for Developing marketing Study Plan" (N=48) Post-marketing Study Plan" 3,6% ■ Yes ■ No






All case PMS number / rate



- Janssen*, MSD, Pfizer, and Gilead Sciences
- EFPIA (15 companies)
 - AstraZeneca, Bayer, CHUGAI, CSL Behring*, Ferring, GlaxoSmithKline*, Janssen*, LEO, Lundbeck, Merck Biopharma, Boehringer Ingelheim, Novartis, Novo Nordisk, Sanofi, and UCB
 - *: Companies participating in both of PhRMA and EFPIA


PMS type trend



 The implementation rate of post-marketing surveillance for approved products remained unchanged during the past 4 years.


The proportion of database surveys decreased in 2020 and remained in 2021.

Drug-used result survey PMDA interaction -inquiries timing-




- PMS was conducted for all NCE/innovative biologics products.
- There were 27% of approved drugs which did not conduct PMS.
- For most products without PMS, they were accepted that routine pharmacovigilance activities suffice.

Background of PMS



- The cases of "Initially, Drug use survey was considered, however, after discussion with PMDA, changed to DB survey." were decreased year by year and stays zero since 2020.
- On the other hand, the cases of "Initially, DB survey was proposed but consequently concluded conduct drug use survey after discussion with PMDA" were increased.

Drug-used/Special Drug-used result survey



Number of PMS patients by PMDA Review Office (N=40)

12

14



8

■ Vaccine ■ Office1 ■ Office2 ■ Office3 ■ Office4 ■ Office5

10



All Case Surveys Non-All Case

Reason for Database Survey NOT planned

12


30

15


18

40

10




"Procedures for Developing Post-marketing Study Plan". The number/rate of "all case surveillance" has not changed for 4 years.



——All case PMS (Number) ——All case PMS (rate)

Drug-used result survey PMDA interaction -agreement timing-



42% of the surveys had submitted protocols by the time of the initial interview.

- 71% of the first inquiries related to PMS were issued by the time of inquiries after initial meeting.
- However, in 68% of the surveys, the protocols, registration forms, and survey forms were agreed with PMDA after the BUKAI meeting.

Drug-used/Special Drug-used result survey

-Survey period and cost-**Observation Period per Patient** 2017 N=44 4 19 8 7 6 2017 N=44 5 22 8 6 3 7 19 5 3 6 5 7 2019 N=37 7 13 7 3 5

9 2 ■~1Y ■1~2Y ■2~3Y ■3~5Y ■>5Y



Monitoring Cost 2018 N=40 5 3 2020 N=35 2 5 1 1 2021 N=41

13

19

2020 N=35


Cost of PMS excluding of monitoring cost




2020 N=35



Drug-used/Special Drug-used result survey -Survey tools-



In the all-case survey, Hybrid is the most.



resources'

Data can not be collected through DB

Lack of understanding about DB in company 6, 15%

Outcome validation is too complicated 1.2%

Not enough time for registry reliability 1, 2%

DB is not suitable to evaluate specific risk 0, 0%

Combine to exsisting study 2, 5%

PMDA requested 1, 2%

Lack of experience 0, 0%

Other 1, 2%

0


10

20

*: Drug-used result survey includes Drug used result survey, Special drug-used result survey and Comparative Drug-used result survey

- 15% of all surveys were DB surveys. • The main reason for selecting the DB surveys was "Suitable DB available for the disease and risk".
- 85% of all surveys were Drug-used result surveys. The main reason for not selecting the
- DB survey was "Data can not be collected through DB"


Organization for DB study management




Mainly, DB study was managed by safety Department in Japan. Slim majority, global epidemiologist participated in the planning of DB Study concepts.



Database Survey -type, agreement timing and cost-Database used for DB Survey



PMS Trend




Global interaction on PMS protocol approval


11

14

17




•	About 60% of companies, there was no global contact point for PMS departments.
•	More than 80% of companies required approval from Global for the contents of
	the PMS protocol
•	About 90% of the companies needed to confirm the answer of PMDA inquiries
	before submission
•	Although GPSP is a local regulation in Japan, Global was involved.




-Termination of all-case surveillance-

PMS Trend -Obtaining Informed Consent-




• The items of informed consent varied among companies.






PMS Trend: Disclosure




- 94% stated disclosure in the implementation plan or implementation guidelines beside re-examination
- In addition, all companies published the PMS results at conferences, in papers, etc. 67% of the respondents publishing on the company website and/or preparing paper brochures or PDFs (created by the PMS department).

PMS Trend : Under Covid-19 Electronic approval (electronic signature)



PMS Trend: Disclosure -Feedback target/timing-



- In the case of paper booklet or PDF (created by the PMS department), 58% were distributed only for medical institutions participating in the survey, and 42% were distributed for all medical institutions to which they deliver or without restrictions.
- Regarding the paper booklet and PDF (prepared by the PMS department), 83% of the companies also prepared interim reports. The data were published at an early stage without waiting for the survey to be completed, indicating the effective use of PMS data outside of proactive re-examination.

PMS Trend : Under COVID-19 -PMDA Interaction-

